-
A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy
This is a 12-month, Phase 3, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of daily DBV712 250 µg in peanut-allergic children aged ...Phase
Interventional
